氨氯地平及阿折地平对高血压病患者血浆炎性介质hs-CRP和TIMP-1的影响

The influence of amlodipine and azelnidipine on serum levels of hs-CRP and TIMP-1 of hypertensive patients

目的探讨长效二氢吡啶类(DHPS)降压药物氨氯地平、阿折地平对高血压病患者血浆炎性介质超敏C反应蛋白(hs-CRP)、1-型组织基质金属蛋白酶抑制物(TIMP-1)浓度的影响。方法将55例高血压病患者随机双盲分为氨氯地平组(28例)和阿折地平组(27例),2组经过2周的药物洗脱期后,分别给予8周的氨氯地平(5～10mg/d)或阿折地平(8～16mg/d)治疗,在治疗前后对血压情况及hs-CRP、TIMP-1进行监测。结果2组患者治疗后收缩压和舒张压均显著下降,血压达标率分别为67.9%和70.4%。氨氯地平组hs-CRP治疗前后分别为(4.48±4.64)mg/L、(1.49±1.62)mg/L,阿折地平组分别为(3.44±1.58)mg/L、(1.19±0.95)mg/L;氨氯地平组TIMP-1治疗前后分别为(78.31±46.21)ng/ml、(55.12±31.17)ng/ml,阿折地平组分别为(73.89±27.69)ng/ml、(45.69±16.87)ng/ml,均显著下降(P均<0.05)。结论氨氯地平和阿折地平对高血压病患者在有效降压的同时,均能降低血浆中炎性介质hs-CRP、TIMP-1的含量,可能在一定程度上降低高血压靶器官的损伤。

Objective To investigate the effects of amlodipine and azelnidipine on the change of serum levels of inflammatory factors hs-CRP and TIMP-1 in hypertensive patients.Methods 55 hypertensive patients were randomly divided into two groups for amlodipine and azelnidipine treatment.After two-week drug clearance,the patients were treated with amlodipine （5-10 mg/d） or azelnidipine （8-16 mg/d） for 8 weeks.The blood pressure and levels of inflammatory factors hs-CRP and TIMP-1 were monitored before and after treatment,respectively.The data of different treatment groups were compared.Results Treatment with amlodipine and azelnidipine could cause the significant decrease of systolic blood pressure.Levels of hs-CRP in amlodipine group were （4.48±4.64） mg/L and （1.49±1.62） mg/L before and after treatment respectively,while those were （3.44±1.58） mg/L and （1.19±0.95） mg/L in azelnidipine group.Levels of TIMP-1 in amlodipine group were （78.31±46.21） ng/ml and （55.12±31.17） ng/ml before and after treatment respectively,while those were （73.89 ±27.69） ng/ml and （45.69 ±16.87） ng/ml in azelnidipine group.Conclusions Eight-week treatment for hypertensive patients with amlodipine and azelnidipine can significantly decrease the blood pressure and the levels of inflammatory factors hs-CRP and TIMP-1. It suggests that the two drugs could improve the inflammatory damage of hypertensive patients.